Showing 2623 results
- https://www.novartis.com/news/media-releases/sandoz-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us-immunology-spaceHyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…
- https://www.novartis.com/news/media-releases/novartis-will-appeal-us-court-appeals-uphold-validity-entresto-combination-patent-maintains-2023-guidance-and-mid-term-outlookAd hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal…
- https://www.novartis.com/about/executive-committee/michelle-weese
- https://www.novartis.com/news/media-library/michelle-weese
- https://www.novartis.com/news/novartis-financial-results-q2-2023
Novartis announced the company’s financial results for the second quarter and first half of 2023.
- https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharmaDTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid ligand-conjugated…
- https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15-billion-share-buyback-and-board-endorses-sandoz-spin-off12Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
- https://www.novartis.com/news/media-releases/novartis-realise-une-forte-croissance-de-son-chiffre-daffaires-et-de-sa-marge-releve-ses-previsions-et-annonce-un-rachat-dactions-dusd-15-milliards1-le-conseil-dadministration-approuve-le-spin-de-sandoz2Annonce événementielle au sens de l’art. 53 LRAu T2, hausse du chiffre d’affaires de +9% (tcc3, +7% USD) et du résultat opérationnel core de +17% (tcc, +9% USD)Innovative Medicines (IM): hausse du…
- https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatz-und-margensteigerungen-und-erhoht-die-prognose-aktienruckkaufprogramm-von-usd-15-milliarden-angekundigt-der-verwaltungsrat-unterstutzt-den-spin-von-sandoz12Ad-hoc-Mitteilung gemäss Art. 53 KRDer Umsatz wuchs im zweiten Quartal um +9% (kWk3, +7% USD), und das operative Kernergebnis verbesserte sich um +17% (kWk, +9% USD)Innovative Medicines (IM…
- https://www.novartis.com/news/media-releases/novartis-announces-new-one-year-results-demonstrating-sustained-secukinumab-efficacy-ankylosing-spondylitis-patients74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page